NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage biotechnology company developing breakthrough cell therapy solutions for severe diseases such as ALS and diabetes, announced the signing of a Memorandum of Understanding between Kadimastem and TargetGene Biotechnologies, which deals in precision gene-editing technologies. This collaboration brings together Kadimastem’s proprietary cell therapy platforms with TargetGene’s DNA-guided gene-editing platform, enabling highly specific, multiplexed genome modifications with minimal off-target activity. The collaboration is expected to continue under the combined company, NewCelX, upon completion of the anticipated merger between NLS and Kadimastem. Pursuant to the MOU, the companies will jointly develop and optimize gene-edited cell therapy products. The MOU establishes a framework for joint R&D activities, technology exchange, and future licensing opportunities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics and Kadimastem Secure Nasdaq Approval for Merger
- NLS Pharmaceutics receives Nasdaq approval for listing
- NLS Pharmaceutics Announces Strategic Merger with Kadimastem
- NLS Pharmaceutics Shareholders Approve Merger with Kadimastem
- Closing Bell Movers: Oracle ticks higher as Trump rescues TikTok in US